Investigating genetic factors in hemophilia patients of Mexican descent
Official title: Omic Approaches to Factor VIII Inhibitor Development in Hemophilia Patients of Mexican Descent
Funded at University of Texas Rio Grande Valley · NIH-10891149 · Data updated 2026-11-12
This study is looking into why some people with severe hemophilia A, especially those of Mexican descent, develop antibodies that make their treatment less effective, and it aims to gather information and samples from these patients to help find better ways to treat them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Rio Grande Valley NIH-funded |
| Lab location | 1 site (Edinburg, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $685,621 |
| NIH project number | 1R01HL169763-01A1 |
| Project ID | NIH-10891149 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are severe hemophilia A patients of Mexican descent, particularly those who may be at risk of developing FVIII inhibitors.
✕Less likely to help
Patients with hemophilia A who are not of Mexican descent may not benefit directly from the findings of this research.
What this research studies
This research focuses on understanding why a significant number of severe hemophilia A patients, particularly those of Mexican ancestry, develop antibodies that neutralize treatment. By enrolling and characterizing a cohort of severe hemophilia patients, the study will collect clinical data and blood samples to assess the risk of developing these inhibitors. Advanced techniques, including whole genome sequencing and mRNA sequencing, will be employed to analyze genetic and environmental factors contributing to this issue. The goal is to improve treatment outcomes for affected patients by identifying the underlying causes of inhibitor development.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for hemophilia A patients, reducing the incidence of inhibitor development and improving patient quality of life.
How similar studies have gone: Previous research has shown success in identifying genetic factors related to hemophilia, but this specific approach focusing on Mexican ancestry is relatively novel.
Where this research is happening
-
University of Texas Rio Grande Valley
Edinburg, United States Active
Researchers
- Principal investigator: Howard, Tom Eugene — University of Texas Rio Grande Valley
- Study coordinator: Howard, Tom Eugene
Related research
Other NIH-funded projects on the same topics.
-
cGMP production of FVIII-making placental cells to help people with Hemophilia A
A new, patient-friendly therapy aims to make FVIII-producing placental cells in the lab to help adults with Hemophilia A, potentially offering a longer-lasting and more affordable treatment.
-
Enhancing immune regulation in gene therapy for hemophilia (new approaches to safer treatment)
A patient-focused overview of a long-running NIH grant exploring how to make gene therapy for hemophilia safer by teaching the body’s immune system to tolerate the therapeutic protein.
-
A safer, longer-lasting gene delivery approach for Hemophilia A using improved nonviral vectors
Researchers are testing a new type of nonviral gene delivery that could provide longer expression of a therapeutic gene for adults with Hemophilia A.
-
Non-viral gene therapy approach to permanently fix hemophilia B
A new gene therapy approach aims to permanently correct hemophilia B without using viruses, potentially reducing bleeding events for people with this condition.
-
Hemophilia Point-of-Care Test Gets Regulatory Ready
A new point-of-care test for hemophilia A measures FVIII and emicizumab to help doctors manage bleeding risk quickly, with plans to obtain regulatory clearance.
-
Hemophilia A: studying why some people develop inhibitors to FVIII across families
This NIH grant funds a multi-year program to follow families affected by severe hemophilia A to understand why some individuals develop antibodies against factor VIII.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.